Seeking Alpha

A panel of non-FDA medical experts votes 11 to 2 not to approve Zogenix's (ZGNX) Zohydro, a...

A panel of non-FDA medical experts votes 11 to 2 not to approve Zogenix's (ZGNX) Zohydro, a hydrocodone pill for chronic pain. Several panel members said they were concerned that the product - which falls into the same drug class as powerful pain products such as OxyContin - didn't contain any features that would prevent drug abusers from tampering with the pill to get all of the active ingredient out at once. ZGNX CEO Hawley and President Farr will hold a conference call to discuss the outcome at 6:30 pm EST. (Webcast)
Comments (1)
  • Aftershock
    , contributor
    Comments (4) | Send Message
     
    Non-Medical experts....for crying out loud.....Everyone wants to jump ship already.FDA cleared Zohydro after it's successful Phase III clinical trials. And a little FYI, Oxy users can still tamper with the pill. There is to be a huge education program for patients from their physicians when this does get approved in March.
    9 Dec 2012, 06:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs